Ali Ibrahim, A., Abdel Khalik, H., Taha, L., rezk, S. (2023). Urotensin II in Psoriasis in relation to disease severity .. Benha Medical Journal, 40(Annual conference issue), 273-282. doi: 10.21608/bmfj.2023.187820.1749
Adel Ali Ali Ibrahim; Hamasat Abdel Hafeez Abdel Khalik; Laila Wafaa Taha; Shymaa Mostafa rezk. "Urotensin II in Psoriasis in relation to disease severity .". Benha Medical Journal, 40, Annual conference issue, 2023, 273-282. doi: 10.21608/bmfj.2023.187820.1749
Ali Ibrahim, A., Abdel Khalik, H., Taha, L., rezk, S. (2023). 'Urotensin II in Psoriasis in relation to disease severity .', Benha Medical Journal, 40(Annual conference issue), pp. 273-282. doi: 10.21608/bmfj.2023.187820.1749
Ali Ibrahim, A., Abdel Khalik, H., Taha, L., rezk, S. Urotensin II in Psoriasis in relation to disease severity .. Benha Medical Journal, 2023; 40(Annual conference issue): 273-282. doi: 10.21608/bmfj.2023.187820.1749
Urotensin II in Psoriasis in relation to disease severity .
1Professor of Dermatology, Venerology and Andrology Faculty of Medicine – Benha University
2Lecturer of Clinical and Chemical Pathology Faculty of Medicine – Benha University
3Department of Dermatology- Faculty of Medicine- Benha University
4Lecturer of Dermatology, Venereology and Andrology Faculty of Medicine - Benha University, Egypt
Abstract
Background: Up to 3% of people worldwide suffer from the chronic inflammatory skin condition psoriasis. When combined with risk factors for atherosclerosis, psoriasis may increase the incidence of metabolic syndrome and other cardiovascular diseases. Urotensin II (UII) is a vasoactive peptide that has been suggested to be increased in metabolic syndrome. Aim: It was to analyze the connection between the severity of the illness and the serum level of Urotensin II (UII) in psoriasis patients. Methods: 40 psoriasis patients and 40 control participants participated in this study who were age- and sex-matched. The cases underwent a thorough history taking and clinical examination, along with an evaluation of the extent and severity of the psoriasis. All subjects' serum UII and lipid profile were measured using ELISA. Results: The case and control groups' fundamental demographic and clinical data did not statistically differ from one another. When compared to the control group's median level of 3.78 ng/ml (1.28- 17.35) of Urotensin II , the level in patients’ group was statistically higher 26.26 ng/ml (5.99-48.12) (p 0.001). The best urotensin II cutoff point for identifying psoriasis cases from controls was > 12.825 ng/ml, with 97.5 percent sensitivity, 90 percent specificity, 95 percent NPV, 97.5 percent PPV, and a total accuracy of 92.5 percent. With a statistically significant value of (< 0.001), the AUC was 0.987 Conclusion: Based on our findings, Urotensin II could be used to diagnose psoriasis in susceptible people.
View on SCiNiTO
Top